Novo Nordisk A/S – Reduction of the share capital

Bagsværd, Denmark, 26 April 2023 – At Novo Nordisk’s Annual General Meeting on 23 March 2023, it was decided to reduce the company’s B share capital from DKK 348,512,800 to DKK 343,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 5,000,000 divided into 25,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 5,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 451,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 343,512,800.

The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Ambre Brown Morley
+45 3079 9289

Natalia Salomao Abrahao (US)
+1 848 304 1027

Daniel Muusmann Bohsen
+45 3075 2175

Jacob Martin Wiborg Rode
+45 3075 5956

David Heiberg Landsted
+45 3077 6915
Mark Joseph Root (US)
+1 848 213 3219

Company annuncement No 27 / 2023